Aflibercept (Eylea): A monthly intravitreal injection for wet age-related macular degeneration (AMD)
New molecular entity: Aflibercept once-monthly intravitreal injection is FDA approved to treat patients with wet (neovascular) age-related macular degeneration.
On November 18, 2011, FDA approved aflibercept once-monthly intravitreal injection indicated to treat patients with wet (neovascular) AMD.
Efficacy. Aflibercept's efficacy was established in 2 randomized, multicenter, double-masked, active-controlled trials (VIEW1 and VIEW2) enrolling 2,412 patients (mean age of 76 years) with wet AMD. Patients were randomly assigned to 1 of 4 dosing regimens: 1) aflibercept administered 2 mg every 8 weeks following 3 initial monthly doses; 2) aflibercept administered 2 mg every 4 weeks; 3) aflibercept 0.5 mg administered every 4 weeks; and 4) ranibizumab administered 0.5 mg every 4 weeks. In both studies, the primary efficacy end point was the proportion of patients who maintained vision, defined as losing fewer than 15 letters of visual acuity at week 52 compared to baseline. Aflibercept 2 mg every 8 weeks and aflibercept at 2 mg every 4 weeks were found to be as efficacious and clinically equivalent to ranibizumab 0.5 mg every 4 weeks.
Safety. In the VIEW1 and VIEW2 clinical trials, the most common adverse events (occurring in >5%) seen in aflibercept patients were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure. Intravitreal injections have been associated with endophthalmitis and retinal detachment, and therefore proper injection technique must be used during administration of aflibercept. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed accordingly. Elevated intraocular pressure is common acutely following intravitreal injection of aflibercept. Sustained increase in pressure should be monitored and may cause perfusion to the optic nerve. Although uncommon (<2% of participants) in these clinical trials, arterial thromboembolic events did occur following intravitreal use of aflibercept. Aflibercept is contraindicated in patients with ocular or periocular infections or active ocular inflammation.
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
